Home

Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.

The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.

 

Prof. David Gandara discusses the latest progress in EGFR, ALK, and checkpoint inhibitor therapies for NSCLC that was discussed at the IASLC WCLC 2017 congress in Yokohama

Medical education slider

Fundamentals of designing clinical trials

Phase III trial design in oncology and principles of article submission

Now available!

memo – inOncology SPECIAL ISSUE
Congress Report WCLC 2017
Congress Report WCLC 2017
The latest findings to come out of the WCLC 2017 congress

Now available!

News

WCLC Yokohama
memo – inOncology SPECIAL ISSUE
Congress Report WCLC 2017
Highlights include the latest clinical trial results for the PD-L1 inhibitors atezolizumab and durvalumab, new data for the PD-1 inhibitor nivolumab and the toll-like receptor 9 agonist lefitolimod; a discussion of the optimal succession of targeted agents across several treatment lines for both EGFR and ALK positive disease; positive data for combined dabrafenib/trametinib therapy for BRAF-positive lung cancer patients; and lots more besides.
Now available!

 

Medical education Fundamentals of designing clinical trials: Part 4: Phase III trial design in oncology and principles of article submission

Sensible endpoint selection design is a critical part of oncological clinical trial design, and is explored here.  This issue looks at the usage of QOL as an endpoint, and discusses the critical aspects of…READ MORE


 

Expert interviews at WCLC

IASLC 18th WCLC 2017, Yokohama
Prof. David Gandara discusses the latest progress in EGFR, ALK, and checkpoint inhibitor therapies for NSCLC.

IASLC 18th WCLC 2017, Yokohama
Prof. Keunchil Park discusses how lung cancer treatments have developed since the advent of chemotherapy, and how best to deliver optimal care to lung cancer patients worldwide, and specifically in South Korea and Japan.

IASLC 18th WCLC 2017, Yokohama
Prof. Ramaswamy Govindan discusses the importance of chemotherapy in today’s treatment landscape, and the importance of ethnic genomic differences in mutation rates in lung cancer.

IASLC 18th WCLC 2017, Yokohama
Prof. Paul A. Bunn discusses current and future treatment options in lung cancer.